[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Abemaciclib",
            "Result": [
                "Score: -2 \u2013 Reasoning:\n\nAcross all five abstracts (PMID: 595758, 825408, 375061, 336137, 701740), the consistent finding is that adding abemaciclib to endocrine therapy does not significantly alter progression-free survival (PFS) or overall survival (OS) compared to endocrine therapy alone. For instance, PMID: 595758 reports a hazard ratio (HR) for PFS of 0.95 with p=0.62, indicating no difference between groups. All other studies likewise show HRs near 1.0 with no statistically significant worsening of survival outcomes.\n\nAlthough abemaciclib-treated patients experienced higher rates of adverse events (e.g., increased neutropenia and diarrhea), none of the abstracts showed that treatment with abemaciclib actively shortened survival or increased disease progression rates relative to controls. Thus, across these texts, there is consistent evidence refuting the hypothesis that abemaciclib worsens breast cancer outcomes in terms of survival metrics. The drug may introduce more toxicity, but there is no evidence of detrimental survival effects. Consequently, the hypothesis \u201cTreatment with Abemaciclib will worsen Breast Cancer patient outcomes\u201d is refuted."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 595758. **Title:** A Phase III Randomized Controlled Trial Evaluating the Efficacy of Abemaciclib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Negative Outcome Study  \n\n**Objective:** To assess the efficacy and clinical benefit of abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, in combination with endocrine therapy versus endocrine therapy alone in patients with advanced hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer.  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Participants were stratified by metastatic site and prior endocrine therapy exposure.  \n\n**Participants:** Eligible patients (n = 450) were postmenopausal women with HR+/HER2- advanced breast cancer who had progressed on prior endocrine therapy. Median age was 58 years (range: 32\u201375), with 60% having visceral metastases.  \n\n**Interventions:** Patients were randomized 1:1 to receive abemaciclib (150 mg twice daily) plus fulvestrant (500 mg IM every 28 days) or placebo plus fulvestrant. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** After a median follow-up of 24 months, no significant difference in PFS was observed between the abemaciclib and placebo arms (median PFS: 12.1 vs. 11.8 months; hazard ratio [HR] 0.95, 95% CI 0.78\u20131.16; p = 0.62). Similarly, OS did not differ significantly (median OS: 28.3 vs. 27.9 months; HR 0.98, 95% CI 0.82\u20131.18; p = 0.84). ORR was comparable between groups (18.2% vs. 16.7%; p = 0.71). Grade 3/4 adverse events were more frequent with abemaciclib (neutropenia: 25% vs. 2%; diarrhea: 12% vs. 1%).  \n\n**Conclusions:** In this randomized trial, the addition of abemaciclib to fulvestrant did not significantly improve PFS or OS in patients with advanced HR+/HER2- breast cancer. The lack of clinical benefit, coupled with increased toxicity, suggests limited utility of this regimen in the studied population. Further biomarker-driven studies may be warranted to identify potential responders.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 825408. **Title: A Phase III Randomized Controlled Trial Evaluating the Efficacy of Abemaciclib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Negative Outcome Study**  \n\n**Background:** Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has been approved for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer. However, recent data have raised questions about its comparative efficacy in certain patient populations. This study aimed to evaluate the impact of abemaciclib on progression-free survival (PFS) and overall survival (OS) in a real-world cohort.  \n\n**Population:** Patients (n=450) with HR+, HER2- advanced breast cancer who had progressed on prior endocrine therapy were enrolled. Median age was 58 years (range: 32\u201379), and 65% had visceral metastases.  \n\n**Intervention:** Patients were randomized 1:1 to receive abemaciclib (150 mg twice daily) plus fulvestrant (500 mg intramuscularly every 28 days) or fulvestrant alone.  \n\n**Comparison:** The control arm received fulvestrant monotherapy. Stratification factors included prior chemotherapy, metastatic site, and menopausal status.  \n\n**Outcomes:** The primary endpoint was PFS, with secondary endpoints including OS, objective response rate (ORR), and safety. Median follow-up was 24 months. No significant difference in PFS was observed between the abemaciclib and control arms (median PFS: 12.1 vs. 11.7 months; hazard ratio [HR]=0.95, 95% confidence interval [CI]: 0.78\u20131.16; p=0.62). Similarly, OS did not differ significantly (median OS: 28.3 vs. 27.9 months; HR=1.02, 95% CI: 0.84\u20131.24; p=0.83). ORR was 18.2% with abemaciclib versus 15.6% with fulvestrant alone (p=0.42). Grade \u22653 adverse events were more frequent with abemaciclib (56% vs. 32%), primarily due to neutropenia and diarrhea.  \n\n**Conclusion:** In this randomized trial, the addition of abemaciclib to fulvestrant did not significantly improve PFS or OS in patients with HR+, HER2- advanced breast cancer. These findings suggest limited clinical benefit in this population, warranting further investigation into predictive biomarkers for CDK4/6 inhibitor response.  \n\n**Trial Registration:** ClinicalTrials.gov NCTXXXXXXX.  \n\n**Keywords:** Abemaciclib, CDK4/6 inhibitor, hormone receptor-positive breast cancer, progression-free survival, overall survival.\n\n---\n\nPMID: 375061. **Title:** A Phase III Randomized Controlled Trial Evaluating the Efficacy of Abemaciclib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Negative Outcome Study  \n\n**Objective:**  \nThis study aimed to assess the efficacy of abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, in combination with endocrine therapy versus endocrine therapy alone in patients with advanced hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. The primary objective was to determine whether abemaciclib significantly improves progression-free survival (PFS) in this patient population.  \n\n**Design:**  \nA multicenter, randomized, double-blind, placebo-controlled phase III trial was conducted. Patients were stratified by metastatic site (visceral vs. non-visceral) and prior endocrine therapy. Randomization was performed in a 1:1 ratio to either abemaciclib plus endocrine therapy or placebo plus endocrine therapy.  \n\n**Participants:**  \nEligible participants were postmenopausal women (n = 450) with HR+, HER2- advanced breast cancer who had progressed on prior endocrine therapy. Median age was 58 years (range: 32\u201375), and 65% had visceral metastases at baseline.  \n\n**Interventions:**  \nPatients received either abemaciclib (150 mg orally twice daily) plus fulvestrant (500 mg intramuscularly on days 1 and 15 of cycle 1, then day 1 of subsequent cycles) or placebo plus fulvestrant. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:**  \nThe primary endpoint was PFS, assessed by RECIST v1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:**  \nAfter a median follow-up of 24 months, the median PFS was 12.1 months (95% CI: 10.3\u201314.0) in the abemaciclib arm versus 11.8 months (95% CI: 9.9\u201313.5) in the placebo arm (hazard ratio [HR] = 0.95; 95% CI: 0.78\u20131.16; p = 0.62). No significant difference in OS was observed (HR = 1.02; 95% CI: 0.82\u20131.27; p = 0.85). ORR was 18.2% with abemaciclib versus 16.7% with placebo (p = 0.71). Grade 3/4 adverse events were more frequent with abemaciclib (45% vs. 22%), primarily neutropenia and fatigue.  \n\n**Conclusions:**  \nIn this randomized phase III trial, the addition of abemaciclib to fulvestrant did not demonstrate a statistically significant improvement in PFS or OS compared to fulvestrant alone in patients with advanced HR+, HER2- breast cancer. The lack of clinical benefit, coupled with increased toxicity, suggests limited utility of abemaciclib in this setting. Further biomarker-driven studies may be warranted to identify potential responder subgroups.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 336137. **Title: A Phase III Randomized Controlled Trial Evaluating the Efficacy of Abemaciclib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Negative Outcome Study**  \n\n**Abstract**  \n\n**Introduction:** Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has shown promise in preclinical studies for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer. However, conflicting clinical data warrant further investigation into its real-world efficacy. This phase III trial aimed to assess whether the addition of abemaciclib to standard endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in this patient population.  \n\n**Methods:** In this multicenter, double-blind, placebo-controlled study, 450 patients with HR+/HER2- advanced breast cancer were randomized 1:1 to receive either abemaciclib (150 mg twice daily) plus ET (letrozole or fulvestrant) or placebo plus ET. The primary endpoint was PFS, with secondary endpoints including OS, objective response rate (ORR), and safety. Stratification factors included prior chemotherapy and metastatic site involvement. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with significance set at p < 0.05.  \n\n**Results:** After a median follow-up of 24 months, no significant difference in PFS was observed between the abemaciclib and placebo arms (median PFS: 14.2 vs. 13.8 months; hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.78\u20131.16; p = 0.62). Similarly, OS did not differ significantly (median OS: 32.4 vs. 31.7 months; HR 0.98, 95% CI 0.82\u20131.18; p = 0.84). ORR was comparable between groups (28.3% vs. 26.1%; p = 0.54). Grade \u22653 adverse events were more frequent with abemaciclib (45.2% vs. 22.6%), primarily due to neutropenia and diarrhea.  \n\n**Discussion:** This study failed to demonstrate a statistically significant benefit of abemaciclib in improving PFS or OS when added to ET in HR+/HER2- advanced breast cancer. The lack of efficacy, coupled with increased toxicity, suggests limited clinical utility in this setting. Further biomarker-driven studies may be needed to identify potential subgroups that could derive benefit from CDK4/6 inhibition.  \n\n**Keywords:** Abemaciclib, CDK4/6 inhibitor, hormone receptor-positive breast cancer, HER2-negative, randomized controlled trial, negative outcome.  \n\n(Word count: 275)\n\n---\n\nPMID: 701740. **Title: Evaluation of Abemaciclib Efficacy in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Randomized Controlled Trial**  \n\n**Abstract**  \n\n**Introduction:** Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has been approved for the treatment of hormone receptor-positive (HR+), HER2-negative advanced breast cancer. While preclinical studies suggested robust antitumor activity, real-world clinical outcomes remain controversial. This study aimed to assess the impact of abemaciclib on progression-free survival (PFS) and overall survival (OS) in patients with metastatic HR+/HER2- breast cancer.  \n\n**Methods:** In this multicenter, randomized, double-blind, placebo-controlled trial, 450 patients with metastatic HR+/HER2- breast cancer were enrolled. Participants were randomized 1:1 to receive abemaciclib (150 mg twice daily) plus endocrine therapy (letrozole or fulvestrant) or placebo plus endocrine therapy. The primary endpoint was PFS, with secondary endpoints including OS, objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with a significance threshold of *p* < 0.05.  \n\n**Results:** After a median follow-up of 24 months, no significant difference in PFS was observed between the abemaciclib and placebo arms (median PFS: 14.2 vs. 13.8 months; hazard ratio [HR] = 0.95, 95% confidence interval [CI]: 0.78\u20131.16, *p* = 0.62). Similarly, OS did not differ significantly (median OS: 32.4 vs. 31.7 months; HR = 1.02, 95% CI: 0.84\u20131.24, *p* = 0.85). ORR was comparable between groups (28.5% vs. 26.1%, *p* = 0.54). Adverse events were more frequent with abemaciclib, including grade 3/4 neutropenia (18.3% vs. 2.1%) and diarrhea (12.6% vs. 1.4%).  \n\n**Discussion:** This study found no statistically significant improvement in PFS or OS with abemaciclib compared to endocrine therapy alone in patients with advanced HR+/HER2- breast cancer. The lack of survival benefit, coupled with higher toxicity, suggests limited clinical utility in this population. Further biomarker-driven studies may identify subsets of patients who could derive meaningful benefit from abemaciclib.  \n\n**Keywords:** Abemaciclib, CDK4/6 inhibitor, breast cancer, hormone receptor-positive, HER2-negative, survival outcomes\n\nAvailable PMIDs for Citation: 595758, 825408, 375061, 336137, 701740\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Abemaciclib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Abemaciclib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Abemaciclib will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Abemaciclib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Abemaciclib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Abemaciclib will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Abemaciclib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Abemaciclib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Abemaciclib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Abemaciclib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Abemaciclib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/595758/",
                    "https://pubmed.ncbi.nlm.nih.gov/825408/",
                    "https://pubmed.ncbi.nlm.nih.gov/375061/",
                    "https://pubmed.ncbi.nlm.nih.gov/336137/",
                    "https://pubmed.ncbi.nlm.nih.gov/701740/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]